ArticleFrontiers in oncology2026
Low-dose decitabine combined with camrelizumab for refractory/relapsed mycosis fungoides/Sézary syndrome: a retrospective exploratory study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mycosis fungoides (MF) and Sézary syndrome (SS) are the main subtypes of cutaneous T-cell lymphomas that are characterized by clinical heterogeneity and are difficult to cure. Objective: This retrospective study evaluated the efficacy and immunomodulatory effects of low-dose decitabine combined with camrelizumab, a novel PD-1 monoclonal antibody used to treat patients with refractory advanced MF/SS. Methods: The enrolled patients received decitabine (10 mg/d, days 1-5) combined with camrelizumab (200 mg, day 7) every 4 weeks. The response was assessed and peripheral blood was analyzed for T-cell subsets, cytokines, Lactate Dehydrogenase (LDH), β2-microglobulin levels, and lymphocyte parameters. Adverse events were monitored. Conclusion: The combination regimen showed encouraging preliminary activity and tolerability in this small retrospective cohort, although the efficacy of SS remains suboptimal. These findings are hypothesis-generating and require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.